Psilocybine

Phase 2Small molecule

UUniversity of Zurich

Psilocybine is one of 37 small molecule programs targeting Chronic pain. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic PainActive, not recruiting

Hematopoietic and Lymphatic System NeoplasmNot yet recruiting

Chronic PainPhase 2

Active, not recruiting

Hematopoietic and Lymphatic System NeoplasmPhase 2

Not yet recruiting

Competition

Competitive Landscape

193 competitors in Chronic Pain

#DrugCompanyPhaseTrials

Nucynta

CCollegium Pharmaceutical, Inc.

Phase 3

1 2

Tramadol Plus Acetaminophen

Johnson & Johnson

Phase 3

2 3

MS Contin

Merck & Co.

Preclinical

3 4

Oravescent Fentanyl

CCephalon

Phase 3

1 5

Cymbalta

Alnylam Pharmaceuticals

Preclinical

2 6

Dayvigo

Eisai

Preclinical

1 7

Psilocybine

UUniversity of Zurich

Phase 2

4 8

Intuniv

PPromius Pharma, LLC

Preclinical

1 9

Ultram

Haisco Pharmaceutical Group Co., Ltd.

Preclinical

1 10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Not yet recruiting

Hematopoietic and Lymphatic System Neoplasm

NCT06827054

Q2 2030

Phase 1Recruiting

Study completion

NCT03289949

Clinical

Trials by Indication[1]

Psilocybin1 trial

Clinical, Neurocognitive, and Emotional Effects of Psilocybin in Depressed Patients - Proof of Concept

Completed·UUniversity of Zurich·Phase 2·NCT03715127·55 enrolled

ISS1 trial

Beyond the Self and Back: Neuropharmacological Mechanisms Underlying the Dissolution of the Self

Completed·UUniversity of Zurich·N/A·NCT03736980·140 enrolled

Hematopoietic and Lymphatic System Neoplasm1 trial

Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring Opioids

Not yet recruiting·RRoswell Park Cancer Institute·Phase 2·NCT06827054·20 enrolled

Unspecified1 trial

The Neurobiological Effect of 5-HT2AR Modulation

Recruiting·GGitte Moos Knudsen·Phase 1·NCT03289949·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Psilocybine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Psilocybine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Psilocybine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Zurich company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Zurich

Psilocybine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2030

Trials by Indication[1]

Psilocybin1 trial

ISS1 trial

Hematopoietic and Lymphatic System Neoplasm1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News